Evaluation of Dihydropyridine Derivatives as Aldose Reductase Inhibitors: Enzymatic Screening, Molecular Docking and Ex Vivo Assessment of a Selected Compound in a Lens Model
- 1Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58040, Mexico
- 2Instituto de Investigaciones Agrícolas y Forestales, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58040, Mexico
- 3Centro de Investigación en Alimentación y Desarrollo A.C., Morelia 58341, Mexico
Abstract
Aldose reductase (AR) is a key enzyme in the polyol pathway and has been widely implicated in the development of diabetic complications, including cataract formation. In this work, a series of structurally modified 1,4-dihydropyridine (DHP) derivatives were evaluated as potential AR inhibitors. The compounds were obtained with high purity and subjected to enzymatic screening, exhibiting IC50 values ranging from 1.11 ± 0.07 to 55.34 ± 0.06 µM. The unsubstituted DHP scaffold exhibited intrinsic activity, whereas substitution at the 4-phenyl ring modulated inhibition in a nonlinear manner, reflecting the combined influence of steric and electronic factors on enzyme interactions. Kinetic analysis revealed mixed-type inhibition, indicating that the inhibitory behavior of the DHP derivatives cannot be explained solely by simple competition with the substrate. Molecular docking using the AR–NADP complex identified favorable binding poses and interactions with residues involved in ligand recognition and stabilization, although no direct correlation was observed between predicted docking scores and experimental inhibitory potency. A representative compound (DHP3, IC50 = 1.11 ± 0.07 µM) was elected for ex vivo evaluation in a rabbit lens model under hyperglycemic conditions. Treatment reduced glucose-induced lens opacity by 89.1%, estimated by image-based analysis, and decreased sorbitol accumulation by 57.48% relative to hyperglycemic control, indicating modulation of the polyol pathway at the tissue level. In contrast, no significant changes were detected in calcium content. These findings support the potential of DHP derivatives as a scaffold for aldose reductase inhibition and highlight their ability to attenuate early alterations associated with hyperglycemia in lens tissue. Further studies are required to expand biological validation and optimize their inhibitory profile.
Related
- Phenolic Compounds from Ruta chalepensis Var. angustifolia as Potential HMG-CoA Reductase Inhibitors: Bioactivity-Guided Fractionation and Preliminary Identification of Active Metabolites
- Reduced Ca2+ current, charge movement, and absence of Ca2+ transients in skeletal muscle deficient in dihydropyridine receptor beta 1 subunit
- Toxicological Assessment of Some Synthesized Carbazole Derivatives Using Computational Interaction with CYP2D6 and In Vivo Zebrafish Embryonic Model
- Update of the risk assessment of brominated phenols and their derivatives in food
- Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry
BibTeX
@article{alonsohurtado2026evaluation,
title = {{Evaluation of Dihydropyridine Derivatives as Aldose Reductase Inhibitors: Enzymatic Screening, Molecular Docking and Ex Vivo Assessment of a Selected Compound in a Lens Model}},
author = {Katia Lizbeth Alonso-Hurtado and Tania Méndez-Pérez and Zurisaddai Hernández-Gallegos and Marcos Cajero-Juárez and Pedro Navarro-Santos and José J. Virgen-Ortíz and Mauro M. Martínez-Pacheco},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219642},
url = {https://www.mdpi.com/1422-0067/27/21/9642},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evaluation of Dihydropyridine Derivatives as Aldose Reductase Inhibitors: Enzymatic Screening, Molecular Docking and Ex Vivo Assessment of a Selected Compound in a Lens Model
AU - Katia Lizbeth Alonso-Hurtado
AU - Tania Méndez-Pérez
AU - Zurisaddai Hernández-Gallegos
AU - Marcos Cajero-Juárez
AU - Pedro Navarro-Santos
AU - José J. Virgen-Ortíz
AU - Mauro M. Martínez-Pacheco
PY - 2026
DA - 2026/10/28
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219642
UR - https://www.mdpi.com/1422-0067/27/21/9642
AB - Aldose reductase (AR) is a key enzyme in the polyol pathway and has been widely implicated in the development of diabetic complications, including cataract formation. In this work, a series of structurally modified 1,4-dihydropyridine (DHP) derivatives were evaluated as potential AR inhibitors. The compounds were obtained with high purity and subjected to enzymatic screening, exhibiting IC50 values ranging from 1.11 ± 0.07 to 55.34 ± 0.06 µM. The unsubstituted DHP scaffold exhibited intrinsic activity, whereas substitution at the 4-phenyl ring modulated inhibition in a nonlinear manner, reflecting the combined influence of steric and electronic factors on enzyme interactions. Kinetic analysis revealed mixed-type inhibition, indicating that the inhibitory behavior of the DHP derivatives cannot be explained solely by simple competition with the substrate. Molecular docking using the AR–NADP complex identified favorable binding poses and interactions with residues involved in ligand recognition and stabilization, although no direct correlation was observed between predicted docking scores and experimental inhibitory potency. A representative compound (DHP3, IC50 = 1.11 ± 0.07 µM) was elected for ex vivo evaluation in a rabbit lens model under hyperglycemic conditions. Treatment reduced glucose-induced lens opacity by 89.1%, estimated by image-based analysis, and decreased sorbitol accumulation by 57.48% relative to hyperglycemic control, indicating modulation of the polyol pathway at the tissue level. In contrast, no significant changes were detected in calcium content. These findings support the potential of DHP derivatives as a scaffold for aldose reductase inhibition and highlight their ability to attenuate early alterations associated with hyperglycemia in lens tissue. Further studies are required to expand biological validation and optimize their inhibitory profile.
SN - 1422-0067
ER -